Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025

Lantern Pharma Inc.

2025-Q1 EPS reported -$0.42

Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
Net loss $4.5M ($0.42/share) vs $5.4M ($0.51/share) in Q1 2024; R&D expense $3.3M vs $4.3M.
LP-184 Phase 1a solid tumor trial enrollment expected to finish by end of June 2025; full data readout in Q3 2025.
FDA cleared Phase 1b/2 protocols for LP-184 in TNBC (with olaparib) and STK11/KEAP1-mutant NSCLC.
LP-300 HARMONIC trial additional data including Asian expansion cohort anticipated in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.